Updates are available Correction dated 2022-03-31
Click to view Correction: https://doi.org/10.1038/s41391-022-00530-9
-
Authors
Chesnut, Gregory T.
Tin, Amy L. http://orcid.org/0000-0002-8005-0694
Fleshner, Katherine A.
Benfante, Nicole E.
Vickers, Andrew J.
Eastham, James A.
Sjoberg, Daniel D.
Carlsson, Sigrid V. http://orcid.org/0000-0003-3553-5710
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30-CA008748, K22-CA234400, U01-CA199338-02, P30-CA008748, P30-CA008748, P30-CA008748, P30-CA008748, P30-CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Sidney Kimmel Center for Prostate and Urologic Cancers Prevent Cancer Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 27 July 2021
Revised: 18 October 2021
Accepted: 19 October 2021
First Online: 3 November 2021
Change Date: 31 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41391-022-00530-9
Competing interests
: AJV is named on a patent for a statistical method to detect prostate cancer. The patent application for the statistical model has been licensed and commercialized as the 4Kscore by OPKO Diagnostics. AJV receives royalties from sales of this test and owns stock options in OPKO.
: The study was approved by the Institutional Review Board at Memorial Sloan Kettering Cancer Center.
